- **05/2023**: JeniVision Receives Positive Feedback from Pre-IND Meeting with FDA for JV-MD2 via NIODP for Prevention of Retinopathy of Prematurity (ROP).

- **02/2023**: Dr. Jenny Wang, JeniVision CEO, Invited to Present at the Prestigious International Society for Eye Research (ISER) XXV Biennial Meeting, on "New Perspectives on Ocular Biodisposition from Studies on the Anti-Glaucoma Drug JV-GL1" at the Glaucoma Pharmacology Session. [https://iserbiennialmeeting2023.org/](https://iserbiennialmeeting2023.org/)

- **06/2022**: JeniVision Receives Rare Pediatric Disease Designation from the U.S. FDA for JV-MD2 via NIODP for prevention of Retinopathy of Prematurity (ROP).

- **02/2022**: JeniVision Completes Enrollment to Phase 1B of JV-GL1 Glaucoma Clinical Trial with preliminary results showing excellent safety profile and good efficacy.

- **12/2021**: JeniVision Receives Positive Feedback from Pre-IND Meeting with FDA for JV-DE1 Ophthalmic Solution, a potent, dual prostanoid IP and PAF receptor antagonist, for treatment of signs and symptoms of dry eye disease.

- **12/2021**: Dr. Jenny Wang, JeniVision CEO, to Present at OIS Drug Delivery Innovation Showcase on "Retinal Drugs Delivered by Non-Invasive Ocular Delivery Platform". To watch the presentation recording please visit [https://vimeo.com/652570757](https://vimeo.com/652570757)

- **03/2021**: JeniVision Discovery of Self-Administered, Non-Invasive Ocular Delivery Platform (NIODP).

- **01/2021**: JeniVision Receives FDA Safe to Proceed Letter for IND Application for JV-GL1, a potent EP2 receptor agonist, in patients with open angle glaucoma or ocular hypertension.

- **11/2018**: JeniVision Raises $7M Series A Funding Round from 3 Venture Capital Firms.

- **2017**: JV-GL1 and JV-DE1 patents granted by USPTO